RFP QuestBeta
Awarded · ResultStage · contract

Medicines Discovery Catapult

MEP including Acoustic Consultant/BSL3 Laboratory - Full and complete service for the duration of the project life cycle Validation Centre

ConstructionCPV 45000000 71000000
Value£91k
Awarded30 Apr 2021
Published5 Jul 2021
RegionNorth West
Outcome — awarded

This is a contract result notice, not an open opportunity. Details from the official award data.

Contract value in context
£91ktotal contract value
median £158k
this tender£0£6.5m

This sits in the lower-middle of the Construction band — a mid-scale opportunity. Based on 64,002 valued Construction tenders in our corpus.

The brief

Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers.

Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products.

By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK's onshore diagnostic capability and capacity and the associated supply chain.

The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.

The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need.

Key requirements

What the supplier must deliver

01

By sharing problems, rare expertise and assets

By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

02

Capitalising on the success of the Lighthouse

Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK's onshore diagnostic capability and capacity and the associated supply chain.

Derived from the notice text — always confirm against the original documents.

Buyer intelligence

Make the case to bid

Reveal who to approach at Medicines Discovery Catapult, and generate a go-to-market strategy from their news, accounts and people.

Source & provenance
OCID
56268b4a-af27-42d0-9aaf-3541a1335122
Stage
contract · Contract
Source
Contracts Finder
Buyer ref
MEDDISC001-DN554695-28712316
View the original notice on Contracts Finder

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

Top suppliers & buyers in Construction

Scroll to explore the market network

Medicines Discovery Catapult’s tender network

Assembling the network…

Also open now

Similar open tenders

Boston Leisure Project - Phase 2 MEP works

Boston Borough Council

Closes 17 Jul 2026Construction
Value not publishedValue

CONTRACT FOR CIVIL ENGINEERING – CORING AND TESTING AND/OR LABORATORY SERVICES

The North Yorkshire Council

Closes 28 Jul 2026Construction
£840kValue